SciELO - Scientific Electronic Library Online

 
vol.27 issue3Two Pandemics: A Comparative Sketch between 1918-19 Spanish Flu and COVID-19Emergency Medicine and Palliative Care: The Need for a Joint Agenda author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • Have no similar articlesSimilars in SciELO

Share


Medicina Interna

Print version ISSN 0872-671X

Abstract

NOGUEIRA, Renato Maia et al. Biossimilars: Are They So Similar?. Medicina Interna [online]. 2020, vol.27, n.3, pp.69-71. ISSN 0872-671X.  http://dx.doi.org/10.24950/PV/53/20/3/2020.

Biosimilars are complex proteins of high molecular weight, produced and purified from biologic products, in comparison to generic drugs, biosimilars are biologically similar to the reference drug while a generic is molecularly identical. We focus on the various biosimilar low weight heparins pretending to demonstrate which criteria were chosen to assure the efficacy and safety of these drugs when they were introduced in the market, comparing the recommendations written by various international societies in comparison with the European Medicine Agency guidelines and the criteria used the ensure these goals. It was verified that the evaluation of these drugs was based on laboratory assessment of its biological activity and underpowered studies of immunogenicity, being that the risks were extrapolated from the reference drug. For this reason, using these drugs carries an unacceptable human risk and a high economic risk since the cost of managing adverse complications can easily overwhelm its relative lower cost.

Keywords : Biosimilar Pharmaceuticals; Drugs, Generic; Heparin, Low-Molecular-Weight.

        · abstract in Portuguese     · text in Portuguese     · Portuguese ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License